Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

th several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 will not be successful, that NP-1 will not receive regulatory approval or achieve significant
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013   Oligomerix, ... development of disease modifying therapeutics for Alzheimer,s disease ... completion of its Series B financing, which includes ... warrants that would represent approximately $2.8M in new ... new investors supported the raise. ...
(Date:5/22/2013)... Mass. and NEW ORLEANS ... leader in the field of regenerative medicine, presented new ... economists from Analysis Group (a leading health economics consultancy) ... diabetic foot ulcers (DFU) and venous leg ulcers (VLU) ... The results of this research, which reveal annual costs ...
(Date:5/22/2013)... 22, 2013 AudioNotch ... for tinnitus treatment. AudioNotch is pleased to announce ... clinic locations in both British Columbia and Alberta, ... and hearing services. AudioNotch's tinnitus treatment program is ... entering a Destination Hearing clinic, patients have the ...
(Date:5/22/2013)... Alton Housing Authority was hit by bed bugs. A ... their presence has already caused the company $35,000 for treatment. ... spending, My Cleaning Products shared a way how to ... the report that to clear the infestation , the ... employees also attended a mandatory training on bed bugs, it ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2
... engine dedicated to recruiting exceptional talent to jobs at ... the most rewarding careers on the planet, but they ... StartUpHire website, www.startuphire.com , lists thousands of jobs ... investor, and more. Search agents allow users to ...
... (Pink Sheets: SYNJ), Reports that it has engaged in ... The job of the Director will be to coordinate ... Pinnacle Energy Division. The Company is currently considering ventures ... production, and microwave plasma physics. To that end, the ...
... NOVATO, Calif., March 18 BioMarin Pharmaceutical Inc. (Nasdaq: ... for clinical trial authorization (CTA) for BMN 110 or ... lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or ... Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). BioMarin ...
Cached Biology Technology:StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 2StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 3Syndication Inc. Seeks 'DIRECTOR OF TECHNICAL ENGINEERING' for 'PINNACLE ENERGY' - Its New Alternative Energy Subsidiary 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4
(Date:5/21/2013)... NC Biologists have known for a long time ... why isn,t well understood, particularly for plants. But it ... Lanfear of Australian National University and the U. S. ... to be published 21 May in the journal ... plants have faster-changing genomes. , Drawing from a database ...
(Date:5/21/2013)... considered in the management of natural resources, and ... help them recognize and respond to the relationships ... , Place-Based Conservation: Perspectives from the Social ... Northwest Research Station,s Linda Kruger, can help managers ... is published by Springer Verlag and is available ...
(Date:5/21/2013)... in the body, stem cells in the blood ... into mature immune cells that can fight off ... these cell populations, potentially leading to the development ... a team of researchers led by biologists at ... that, in mouse models, the molecule microRNA-146a (miR-146a) ...
Breaking Biology News(10 mins):Small but speedy: Short plants live in the evolutionary fast lane 2Keeping stem cells strong 2
... the consumption of soy-based foods can cause irreversible changes ... puberty and symptoms of advanced menopause in research animals, ... Carolina State University. The study is a breakthrough in ... as well as in providing a key building block ...
... scientists at the National High Magnetic Field Laboratory at ... petroleum companies to locate, analyze and process crude oil ... Marshall, a giant in the field of chemical analysis, ... with a California-based company, Sierra Analytics ( www.MassSpec.com ), ...
... PASADENA, Calif.--Organisms ranging from humans to plants to the ... the various stages of an organism,s development, and still ... sex. Researchers at the California Institute of Technology have ... the nematode worm Caenorhabditis elegans that serves ...
Cached Biology News:New study shows compounds from soy affect brain and reproductive development 2FSU, Magnet Lab researchers license critical petroleum data 2Caltech researchers find dual-use sexual attraction and population-control chemicals in nematodes 2Caltech researchers find dual-use sexual attraction and population-control chemicals in nematodes 3
... StabilZyme HRP Conjugate Stabilizer is an ... protein and other non-toxic stabilizing chemicals in ... 6.2 6.7. This product contains ... and 20 ppm Proclin 300 (Rohm and ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... and positioning system is designed for ... be positioned or scanned with high ... superior responsiveness compared to micropositioners with ... or XY stage) are driven by ...
Biology Products: